임상1상 용량 증대 - 4번째 용량 시험
Sep 09, 2015MILESTONESHit 278
The third cohort (100 mg) in dose escalation of Phase I clinical trial to evaluate the safety was finished successfully. The safety monitoring committee (SMC) recommended a dose escalation to the next level (140 mg). Three clinical sites in the USA started recruitment of patients with solid tumor for the forth cohort.
|Previous||미국임상, TEW-7197 암환자 투약|
|Next||메드팩토, MSD와 면역항암제 병용 투여 임상 계약|